Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 29 Neoplasms 14 Breast Neoplasms 8 Fallopian Tube Neoplasms 7 Prostatic Neoplasms 4 Neoplasm Metastasis 4 Triple Negative Breast Neoplasms 2 Prostatic Neoplasms, Castration-Resistant 2 Melanoma 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Non-Small-Cell Lung 2 Urologic Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Diseases 1 Pancreatic Neoplasms 1 Ovarian Diseases 1 Osteosarcoma 1 Neuroblastoma 1 Metastatic Castration-sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, Prolymphocytic, T-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Rituximab 63 Cyclophosphamide 37 Brentuximab Vedotin 22 Bendamustine Hydrochloride 22 pembrolizumab 20 fludarabine 20 Gemcitabine 20 Doxorubicin 20 Prednisone 19 ibrutinib 17 Vincristine 16 obinutuzumab 14 Lenalidomide 13 Nivolumab 10 Rifampin 8 parsaclisib 7 duvelisib 7 atezolizumab 7 Vorinostat 7 Dexamethasone 7 Azacitidine 7 spartalizumab 6 loncastuximab tesirine 6 MLN 8237 6 venetoclax 5 ixazomib 5 glofitamab 5 fludarabine phosphate 5 durvalumab 5 acalabrutinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma × niraparib × Clear all

NCT01244009 2016-11-07

A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)

Tesaro, Inc.

Phase 2 Withdrawn

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡